Related Experiment Video
Updated: Jul 14, 2026
07:41
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
An integrated approach to prognosis using protein microarrays and nonparametric methods
Tanya Knickerbocker1, Jiunn R Chen, Ravi Thadhani
1Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA.
Molecular Systems Biology
|June 28, 2007
Summary
This study introduces a personalized approach to predicting patient outcomes using molecular markers and clinical data. Prognostic value of markers depends on patient variables, enabling tailored risk assessment.
Area of Science:
- Biomarkers and Omics
- Clinical Informatics
- Medical Prognosis
Background:
- Multivariate statistical methods are increasingly used for disease diagnosis.
- Identifying reliable prognostic markers for patient outcomes remains challenging.
- Previous studies often overlook the interplay between molecular markers and clinical variables.
Purpose of the Study:
- To develop an integrated approach for disease prognosis using molecular markers and clinical data.
- To investigate non-linear relationships between molecular markers, clinical variables, and patient outcomes.
- To apply this approach to predict early mortality in patients starting kidney dialysis.
Main Methods:
- Utilized protein microarrays to measure a focused set of molecular markers.
- Employed non-parametric statistical methods to analyze complex relationships.
- Integrated molecular data with clinical variables for predictive modeling.
Main Results:
- Molecular markers demonstrated variable prognostic value, contingent on specific clinical variables.
- The integrated approach successfully predicted early mortality in kidney dialysis patients.
- Findings suggest that prognostic marker utility is context-dependent.
Conclusions:
- A personalized approach to prognosis, considering both molecular and clinical data, is crucial.
- This method can enhance the accuracy of predicting patient outcomes.
- Understanding marker-clinical variable interactions is key to advancing personalized medicine.
Related Concept Videos
01:33Proteomics
A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term proteomics...
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term proteomics...
01:24Kaplan-Meier Approach
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...